Background: The treatment of HIV-1-infected patients with triple-drug combination therapy results in profound suppression of viral replication. In most therapy-naive patients plasma HIV-1-RNA levels (pVL) drop below the lower limit of quanti®cation (LLQ) of currently used assays. In a large percentage of such patients, more sensitive assays provide evidence of residual viral replication. The question is whether more potent therapy can further suppress this residual replication.
Introduction
The treatment of HIV-1-infected patients with tripledrug combination therapy can result in profound suppression of viral replication. In most therapy-naive patients plasma HIV-1-RNA levels (pVL) drop below the detection limit of currently used assays, and this can be sustained for a period of at least 3 years [1±3].
However, a reservoir of resting memory CD4 T cells harbouring replication-competent virus has been demonstrated to persist during sustained suppression of pVL [4±7] . The half-life of this cellular reservoir has been estimated to be very long, and it therefore represents a major barrier to the eradication of HIV by antiretroviral therapy [8, 9] . Furthermore, an undetectable pVL using standard assays should not be interpreted as evidence of the complete suppression of viral replication. In a large percentage of patients with undetectable pVL using standard assays, more sensitive assays show evidence of ongoing low-level viral replication. A low pVL (1±20 copies/ml), the expression of viral RNA in lymphoid tissue, and unintegrated circular forms of viral DNA or HIV-1 messenger RNA in peripheral blood mononuclear cells could still be detected in many of these patients despite prolonged therapy [ 9± 23] . Ongoing low-level viral replication below the limit of quanti®cation (LLQ) of standard assays is worrisome, as it may allow for the selection of resistance mutations and subsequent therapeutic failure [9, 22, 24, 25] . Indeed, during potent antiretroviral therapy successfully suppressing pVL to below 50 copies/ ml, new drug resistance mutations were demonstrated in minority populations of viruses cultured from blood cells [24] . Ongoing low-level replication also precludes the eradication of HIV from a patient. To prevent viral resistance and attempt viral eradication, an important question is whether the intensi®cation of antiretroviral therapy might reduce this residual viral replication.
We have previously demonstrated that an alternative multidrug regimen, consisting of three different classes of antiretroviral drugs, resulted in a more rapid initial pVL decline than a standard of care regimen consisting of two different classes, which suggested that the initial viral suppression by standard of care therapy can be improved upon [26] . In this study, we explored, using a modi®ed ultrasensitive HIV-1-RNA assay, whether this multidrug regimen also results in the stronger suppression of viral replication compared with standard of care therapy during prolonged treatment.
Patients and methods
Alternative multidrug regimen group Ten chronically infected HIV-1 patients, aged 31±60 years, started a ®ve-drug regimen with the nucleoside analogue reverse transcriptase inhibitors (NRTI) zidovudine, lamivudine and abacavir, the non-nucleoside reverse transcriptase inhibitor (NNRTI) nevirapine, and the protease inhibitor (PI) indinavir between January 1997 and February 1998 [26] . One patient had previously received antiretroviral therapy: zidovudine for 16.5 months and lamivudine for 10.5 months, both of which were stopped 14 days before enrolment, and didanosine for 6 months, which had been stopped one year before enrolment. This individual received a similar ®ve-drug regimen as the others, except that stavudine was substituted for zidovudine and didanosine was substituted for lamivudine. In cases of toxicity, the drug regimen was changed in individual patients but always consisted of antiretroviral drugs from three different classes during the 144 weeks of follow-up [26, 27] . As a result of toxicity, three patients (002, 006 and 015) decided to stop therapy after 73, 118 and 87 weeks of treatment, respectively. At the moment of discontinuation of therapy these three patients had a pVL below 5 copies/ml, and they were only included in the analysis at week 48. The study was approved by the Medical Ethics Committee of our hospital, and informed consent was obtained from all patients.
Control group
Control patients were selected from the HIV-1-positive patient population at the outpatient clinic of the Academic Medical Center, Amsterdam, the Netherlands. The selection criteria were chronic HIV-1 infection, antiretroviral therapy-naive at the start of a standard potent antiretroviral regimen, start of antiretroviral therapy between July 1996 and February 1998, and no evidence of virological failure during 144 weeks of follow-up. A standard potent antiretroviral regimen was de®ned as a combination regimen containing two different classes of antiretroviral drugs: two NRTI plus one or two PI, or one NRTI plus two PI [28] . Saquinavir hard gel formulation as a single PI plus two NRTI was not considered to be a potent antiretroviral regimen. Treatment modi®cations within the de®nitions of the standard combination regimen for reasons other than virological failure were allowed. Virological failure during the 144 weeks of follow-up was de®ned as having one of the following: (i) not reaching a pVL below the LLQ of the standard assay used at that moment within 24 weeks after starting antiretroviral therapy, or (ii) having a single pVL . 1000 copies/ml or two consecutive pVL measurements between 400 and 1000 copies/ml after having had a pVL below the LLQ. If the last pVL in the 144 week period was between 400 and 1000 copies/ml, the patient was excluded if no subsequent measurement was available.
Each control patient had to have enough frozen plasma available at three different timepoints after 3 years of therapy (week 144, and the ®rst available timepoint before and after week 144) for re-testing in the modi®ed NucliSens HIV-1 QT assay (Organon Teknika, Boxtel, the Netherlands) with a LLQ of 5 copies/ ml [26] .
Plasma HIV-1-RNA quanti®cation
Alternative multidrug regimen group The pVL in ethylenediamine tetraacetic acid plasma was measured every 8 weeks using the NucliSens HIV-1 QT assay (Organon Teknika) with 0.2 ml plasma input, resulting in an LLQ of 400 copies/ml. During the ®rst 16 weeks of antiretroviral therapy, pVL was measured more frequently. When pVL decreased to below 400 copies/ml, an initial input volume in the assay of 2 ml plasma was used combined with an ultrasensitive protocol adaptation, resulting in a LLQ of 5 copies/ml [26] .
Control group
The pVL in ethylenediamine tetraacetic acid plasma was routinely measured every 12 weeks. After the start of antiretroviral therapy, and after a change in regimen, measurements were carried out more frequently for 12 weeks. Before August 1999, pVL was measured using standard HIV-1-RNA assays with a plasma input of 0.1 or 0.2 ml. The NASBA HIV-1 QT assay (Organon Teknika) had an LLQ of 1000 copies/ml, and the NucliSens HIV-1 QT assay and Amplicor HIV Monitor (Roche Diagnostic Systems Inc., Branchburg, NJ, USA) had an LLQ of 400 copies/ml. After August 1999 ultrasensitive HIV-1-RNA assays were used, either the NucliSens HIV-1 QT assay with 2 ml plasma input and an LLQ of 40 copies/ml or Quantiplex branched DNA 3.0 (Bayer Corporation, Tarrytown, NY, USA) with 1 ml plasma input and an LLQ of 50 copies/ml. At the moment the ®rst patient reached week 48, the assays with an LLQ of 400 copies/ml were in use. Plasma from the patients ful®lling the selection criteria, obtained at 48 and 144 weeks after the start of therapy and at the ®rst available timepoint before and after week 144, was re-tested using the NucliSens HIV-1 QT assay with 2 ml plasma input combined with the ultrasensitive protocol adaptation, resulting in an LLQ of 5 copies/ml.
Statistical analysis
Data were analysed using SAS version 8.0 (SAS Institute, Cary, NC, USA). Differences between groups were considered signi®cant at P , 0.05. All reported P values are two-sided.
Group comparisons of baseline CD4 T cell counts, pVL, age, sex, and disease stage were made using the Wilcoxon rank sum test and Fisher's exact test. The primary objective of the study was to compare lowlevel viraemia in both groups during prolonged therapy. We therefore compared differences between the alternative multidrug regimen group and the control group in pVL, as assessed by ultrasensitive testing (LLQ 5 copies/ml), at week 48, and at week 144 and the ®rst available timepoint before and after week 144.
The number of patients in the two groups with a quanti®able pVL at week 48 was compared using Fisher's exact test. The number of timepoints with a quanti®able pVL per patient at and around week 144 (ranging from none out of three to three out of three measurements per patient) was compared using the Cochran±Armitage trend test.
We compared controls with no quanti®able pVL at and around week 144 with controls with one or more samples with quanti®able pVL at and around week 144 for CD4 T cell counts at baseline and week 144, and the pVL at baseline, using the Wilcoxon rank sum test.
Results
Control patients were selected from 111 HIV-1-positive antiretroviral-naive patients who initiated a standard potent antiretroviral regimen between July 1996 and February 1998. Of these 111 patients, 101 had an initial virological response as evidenced by an undetectable pVL within 24 weeks after starting therapy. After 48 weeks, 66 out of 111 patients (60%) and after 144 weeks, 54 out of 111 patients (49%) had not experienced virological failure according to our criteria. Of these 54 patients, 24 had switched to an NNRTIcontaining regimen; 30 patients were still on a standard potent PI-containing regimen. The initial regimens used in these 30 selected control patients are described in Table 1 . Baseline CD4 T cell count, pVL, age, sex, and disease stage were not signi®cantly different for the multidrug regimen group and the control group (Table 1) .
At week 48, one of the 30 control patients had a quanti®able pVL (550 copies/ml) using the then available standard assay. Frozen plasma samples were available for re-testing in the modi®ed ultrasensitive assay (LLQ 5 copies/ml) in 23 of the other 29 control patients; nine of these contained quanti®able pVL. pVL could thus be quanti®ed (range 25±550 copies/ml) in 10 out of 24 control patients (41.7%), whereas in all 10 patients treated with the alternative multidrug regimen pVL was below 5 copies/ml (Fisher's exact test, P 0.017).
At and around week 144, we performed three measurements per patient. Of the 3 3 30 measurements in control patients, seven samples already contained quan-ti®able pVL (range 79±453 copies/ml) using standard assays with an LLQ of 40, 50 or 400 copies/ml. Five of the 30 patients had switched to an NNRTI between week 144 and the ®rst pVL measurement after week 144. In one patient, two samples were not available for re-testing because this patient had been enrolled in another study. One of the samples yielded an invalid test result in the modi®ed ultrasensitive assay despite repeated testing. These eight measurements were not censored, but were considered to be undetectable for the purpose of this study.
At and around week 144, pVL could be quanti®ed either in the standard assays or in the modi®ed ultrasensitive assay (LLQ 5 copies/ml) at none out of three timepoints in 12 control patients, at one out of three timepoints in 14 control patients, and at two out of three timepoints in four control patients (see Fig. 1 ). The measured viraemia varied between 13 and 453 copies/ml. In the seven patients using the alternative multidrug regimen, pVL could be quanti®ed at none out of three timepoints in six patients, and at one out of three timepoints in one patient (21 copies/ml). The number of samples with quanti®able pVL per patient differed signi®cantly between the two groups (P 0.036, Cochran±Armitage trend test).
Of the 10 control patients with a quanti®able pVL at week 48, pVL could be quanti®ed at none out of three timepoints at and around week 144 in two patients, at one out of three timepoints in ®ve patients, and at two out of three timepoints in three patients. Of the 14 control patients with an unquanti®able pVL at week 48, pVL could be quanti®ed at none out of three timepoints in seven patients, and at one out of three timepoints in seven patients (P 0.029, Cochran± Armitage trend test).
Control patients were further divided into a subgroup of 12 patients with no quanti®able pVL at and around week 144, and a subgroup of 18 patients with at least one quanti®able pVL at that moment. The median baseline CD4 T cell count of the 18 control patients with at least one quanti®able measurement was lower than that of the other control subgroup [65 cells/mm 3 , interquartile range (IQR) 30±240 cells/mm 3 and 150 cells/mm 3 , IQR 100±370 cells/mm 3 , respectively; P 0.026, Wilcoxon rank sum test]. Both subgroups were comparable regarding age, sex, disease stage at the start of antiretroviral therapy, baseline HIV-1-RNA levels, CD4 T cell count at week 144, and the drugs used in the standard regimen at baseline and at week 144 (data not shown). The patient using the alternative multidrug regimen who had one quanti®able pVL at and around week 144 had a baseline CD4 T cell count of 110 cells/mm 3 . The other six patients using the alternative multidrug regimen had baseline CD4 T cell counts of 30, 30, 130, 310, 360 , and 450 cells/mm 3 , respectively.
Discussion
This study demonstrates that the use of a multidrug regimen consisting of three different classes of antiretroviral. Although this study was not designed as a comparative study from the start of therapy, we feel justi®ed to draw conclusions from this comparison. The control group was a selection consisting of the most successfully treated patients in our outpatient clinic, who during three years of potent standard antiretroviral therapy had not experienced virological failure using strict criteria. This makes suboptimal compliance with the medication not a likely explanation for the difference in viral suppression between the two groups as . 95% adherence is necessary for optimal virological outcome [29] . Furthermore, we also identi®ed patients who according to our strict criteria experienced virological failure between weeks 48 and 144. These patients were excluded from our analyses, but their virological failure might very well have been caused by ongoing low-level viral replication despite good adherence to their standard potent antiretroviral therapy. During the observation period of 3 years none of the patients in either group used concomitant medications, such as rifampicin or diphantoin, which could interfere with drug levels.
At and around week 144, we performed three measurements per patient. Testing plasma samples with a concentration of HIV-1 RNA below the LLQ of a modi®ed ultrasensitive assay can still yield a positive test result. For instance, using an ultrasensitive assay with an LLQ of 3 copies/ml, the chance of detecting HIV-1 RNA in plasma samples containing 10, 5, 2.5, and 1.25 copies/ml was 100, 100, 91 and 55%, respectively [14] . Therefore, the chance of detecting pVL below the LLQ can be increased by repeated testing of the same blood sample. We preferred measurements of blood samples obtained at different timepoints instead of repeated measurements of the same sample, as by doing this we also allowed for the detection of a possible dayto-day variation in pVL.
The fact that we were able to demonstrate a signi®cantly higher level of plasma viraemia in these highly selected control patients is indicative of the presence of ongoing low-level viral replication in the majority of patients using so-called potent antiretroviral therapy, despite undetectable pVL using standard assays.
The clinical implication of ongoing viral replication is ®rst of all the risk of continued viral evolution and the selection of resistance mutations, which has been demonstrated to occur even in patients with undetectable pVL [9, 22, 24, 25] . Ongoing low-level viral replication might in the long run lead to therapeutic failure. A decrease over time in the percentage of patients with pVL below 50 copies/ml, from 75% after one year to 65% after 3 years of triple therapy, has recently been described [1] . One possible explanation for this late virological breakthrough may be the development of viral drug resistance during ongoing low-level viral replication. Although it is currently not known what degree of virological suppression is necessary to ensure a long-term response, it has been demonstrated that the risk of virological failure was substantially reduced for chronically infected patients whose plasma HIV-1-RNA nadir was below 20 copies/ml [30] .
Furthermore, the presence of a cellular reservoir consisting of resting memory CD4 T lymphocytes harbouring replication-competent virus despite prolonged potent antiretroviral therapy represents a major barrier to the eradication of HIV [4±7]. In treated patients with undetectable pVL the mean half-life of this pool of latently infected memory CD4 lymphocytes has been estimated to be 6±43.9 months, leading to a theoretical time for eradication of HIV-1 by antiretroviral agents alone of 10±60 years [8, 9] . The difference in decay rate has been attributed to differences in the suppression of pVL, because individuals who experienced episodes of plasma viraemia had a slower decay rate of their cellular reservoir [13] . So, the persistence of the cellular reservoir during prolonged treatment is not only determined by its intrinsic slow decay characteristics, but also by continuing replenishment in the case of active viral replication. In line with this is the observed more rapid decay of the cellular reservoir after treatment intensi®cation with abacavir with or without efavirenz in ®ve patients compared with ®ve other patients whose therapy was not intensi®ed [31] .
The question is whether the improved suppression of viral replication should be explained by more drugs or by more classes of drugs used. A possible mechanism for the improved suppression of viral replication using the alternative multidrug regimen is that the presence of more reverse transcriptase inhibitors results in stronger inhibition of the reverse transcription of HIV-1 RNA. Furthermore, suboptimal penetration of antiretroviral drugs into anatomical (e.g. the brain and male genital tract) and cellular sites might result in only partial suppression of viral replication in these sites in the case of standard of care therapy. In the multidrug regimen, the drugs were selected because of their known good penetration into these anatomical sites [27,32±34] . When assuming that combination therapy does not completely block the infection of new cells, but rather results in a decrease in the amplitude of ongoing HIV infection cycles, the use of more antiretroviral drugs could further reduce the size and frequency of these local bursts of viral replication [35] .
A quanti®able pVL at week 48 was predictive of residual viral replication around week 144. Also, a low baseline CD4 T cell count was predictive of residual replication, despite comparable CD4 T cell counts at week 144 for patients with and without quanti®able low-level viral replication. The relationship between a high baseline CD4 T cell count and the stronger suppression of viral replication during standard antiretroviral therapy was demonstrated earlier [14, 36] . An explanation might be that in chronically HIV-1-infected patients with advanced immunosuppression, the capacity to restore a functional HIV-1-speci®c cytotoxic T-lymphocyte response is diminished [37] . The administration of a multidrug regimen may compensate for this diminished HIV-1-speci®c immunity in such advanced patients.
Because of extensive cross-resistance between currently available members of the same drug class, many clinicians fear that using drugs from three different classes in a ®rst-line regimen might limit further treatment options if virological failure should occur. At the moment we do not recommend the use of a ®rst-line triple-class regimen outside the setting of clinical trials.
Conclusion
This proof-of-principle study demonstrates that the use of a multidrug regimen consisting of three different classes of antiretroviral drugs results in a further reduction in pVL compared with treatment with standard potent antiretroviral therapy. This provides evidence that ongoing low-level viral replication during standard therapy is at least partly caused by the limited potency of the currently used drug regimens. It is evident that further long-term follow-up studies are required to answer the important question of whether the advantages of improved viral suppression by this multidrug regimen outweigh the disadvantages of the additional toxicity and costs of using more antiretroviral agents.
